Microvascular Therapeutics, Inc Named 2025 Most Fundable Company® by Pepperdine Graziadio Business School

Salt Lake City (Utah), September 29, 2025: Microvascular Therapeutics (MVT), the leader in development of next-generation ultrasound microbubble and nanobubble technologies, is proud to announce that it has been recognized on the 2025  Pepperdine Graziadio Business School eighth annual Most Fundable Companies^® List. MVT competed against over 2,300 early-stage companies nationwide and is one of only fourteen (14) selected for this distinction.  The List recognizes early-stage U.S. startups that demonstrate strong investor readiness across market opportunity, IP, competitive advantage, and team strength. MVT was selected as the #1 Fan Favorite.

The Most Fundable Companies initiative aims to educate founders on the investor diligence process and recognize exceptional entrepreneurs who are solving today's problems with inventive solutions and are also seeking investment capital to fuel their company's growth. A video of the event is available at www.pepperdine.edu/mfc-list.

“MVT’s mission is simple and ambitious: transform ultrasound from imaging to cure,” said Evan Unger, MD, Founder and CEO of MVT. “This recognition validates our strategy and momentum as we advance our best-in-class ultrasound contrast agent toward pivotal development and bring our nanobubble therapeutics into the clinic.” Dr Unger added that "The Most Fundable Companies initiative” was one of the most intensive processes we've ever participated in, and we're thrilled to have arrived on top through data-driven analysis. We're excited that the Pepperdine Graziadio Business School is giving entrepreneurs a platform to showcase their businesses and set them up for success with investors."As a winner on the Most Fundable Companies^® List, MVT will be profiled on Entrepreneur.com and featured in the November/December print issue of Entrepreneur magazine. For the full list of winners, visit www.pepperdine.edu/mfc-list.

“Evan Unger is the original inventor of Definity®, the market-leading ultrasound contrast agent in echocardiography,” said Timothey Healey, MVT Board Member and Chief Commercial Officer of Eversana, “That history of invention, combined with MVT’s GMP manufacturing capabilities and a robust patent estate, positions the Company to scale both diagnostic and therapeutic product lines.”

About Microvascular Therapeutics

MVT’s lead diagnostic candidate, CardiSon, is a next generation ultrasound contrast agent designed for room-temperature storage and enhanced image quality. In a Phase II study reviewed by independent blinded echocardiographers, CardiSon delivered superior contrast and reduced acoustic shadowing. The Company’s therapeutic nanobubble pipeline includes Solv for acute vascular ischemia (preclinical studies in swine have shown up to ~90% reduction in myocardial injury with a 20-minute treatment) and NanoBlate for non-invasive tumor ablation with focused ultrasound. MVT is preparing a single pivotal trial for CardiSon with FDA guidance in hand and anticipates Solv’s first-in-human studies to begin following current non-dilutive support, with NanoBlate to follow. MVT holds 13 issued U.S. patents protecting its platform. To date, the company has raised $24 million in dilutive and non-dilutive capital and maintains its own certified manufacturing facility to support late-stage development and commercialization.

About Pepperdine Most Fundable Companies

The Most Fundable Companies^® List is an annual program hosted by Pepperdine Graziadio Business School to promote startup business development, provide pathways for funding, and inspire entrepreneurial spirit nationwide. The Most Fundable Companies^® Showcase, presented by the Singleton Foundation for Financial Literacy and Entrepreneurship, took place on September 24, 2025, at Pepperdine University’s Villa Graziadio Executive Center in Malibu, CA.

Launched in 2018, the program is a free resource to help entrepreneurs assess their readiness for private investment. It uses a multi-phase assessment that evaluates key company variables, including financial projections, market opportunity, intellectual property, competitive advantage, and management team strength, generating objective and customized feedback and scoring for each participant.

Disclaimers: The Pepperdine Most Fundable Companies list does not represent an offer to sell securities. It does not constitute investment advice, nor is it an endorsement of any particular product or service. Pepperdine University is not a broker-dealer and does not perform services provided by a broker-dealer, including but not limited to any financial or investment advising.

Contact:

Bryan

Therapeutics, Inc.

b.unger@mvtpharma.com | (520) 977-1210 | www.mvtpharma.com